CYTOGEL PHARMA, LLC
11Patents
11Active
11Granted
45Portfolio score
Filing activity: Jun 9, 2005 → Apr 20, 2022 · 3 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8940704B2 | Advantageous salts of μ-opiate receptor peptides | Human Necessities | 6 | Active |
| US11324798B2 | Materials and methods for treatment of inflammation | Human Necessities | 0 | Active |
| US8034383B2 | Injectable microspheres | Emerging Cross-Sectional Technologies | 0 | Active |
| US8246993B2 | Advantageous hydrogel composition | Human Necessities | 0 | Active |
| US8246994B2 | Method for delivering an active agent using a hydrogel composition | Human Necessities | 0 | Active |
| US12146002B2 | Polymer agonists of mu opioid receptors | Human Necessities | 0 | Active |
| US8092835B1 | Injectable microspheres | Emerging Cross-Sectional Technologies | 0 | Active |
| US12037416B2 | Polymer agonists of mu opioid receptors | Human Necessities | 0 | Active |
| US10441625B2 | Materials and methods for treatment of inflammation | Human Necessities | 0 | Active |
| US10975121B2 | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof | Human Necessities | 0 | Active |
| US11603385B2 | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.